Helsinn and MEI Pharma begin dosing in Phase III combination trial for AML
Swiss pharmaceutical group Helsinn and US-based oncology firm MEI Pharma have begun dosing patients in a Phase III clinical trial of pracinostat and azacitidine combination to treat adults with newly diagnosed acute myeloid leukaemia (AML). (Source: Drug Development Technology)
Source: Drug Development Technology - August 2, 2017 Category: Pharmaceuticals Source Type: news

Mallinckrodt ’s Phase IV registry for PPHN medicine starts enrolment
Mallinckrodt Pharmaceuticals has started patient enrolment in a Phase IV registry (PaTTerN) to evaluate INOMAX (nitric oxide) gas inhalation to treat persistent pulmonary hypertension of the newborn (PPHN). (Source: Drug Development Technology)
Source: Drug Development Technology - August 1, 2017 Category: Pharmaceuticals Source Type: news

Acceleron begins dosing in Phase II trial of ACE-083 to treat CMT
Acceleron Pharma has started dosing patients in a Phase II clinical trial of its therapeutic candidate ACE-083 for the treatment of Charcot-Marie-Tooth disease (CMT) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - August 1, 2017 Category: Pharmaceuticals Source Type: news

Generex combines AE37 with Merck ’s Keytruda in Phase II trial for TNBC
Generex Biotechnology has signed a clinical trial collaboration agreement through its Antigen Express division to combine its cancer vaccine AE37 with Merck ’s Keytruda (pembrolizumab) in a Phase II clinical trial for patients with triple-negative bre… (Source: Drug Development Technology)
Source: Drug Development Technology - August 1, 2017 Category: Pharmaceuticals Source Type: news

FlexyPAT as a Calorimeter
FlexyPAT is a modular process automation technology that enables automated, customer-specific lab reactor systems to be implemented cost-effectively. With FlexyPAT, you have a strong and flexible tool. (Source: Drug Development Technology)
Source: Drug Development Technology - August 1, 2017 Category: Pharmaceuticals Source Type: news

Idorsia reports positive results from Phase II programme of insomnia drug
Swiss biopharmaceutical firm Idorsia has reported positive results from a Phase II programme of ACT-541468 to treat patients suffering from insomnia. (Source: Drug Development Technology)
Source: Drug Development Technology - July 31, 2017 Category: Pharmaceuticals Source Type: news

BMS and Clovis to initiate Phase II and III combination trials for oncology
Bristol-Myers Squibb (BMS) has signed a clinical collaboration agreement to investigate the combination of its Opdivo (nivolumab) with Clovis Oncology ’s Rubraca in a Phase II and two Phase III clinical trials to treat various types of tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - July 31, 2017 Category: Pharmaceuticals Source Type: news

Glenmark ’s Phase IIa study of atopic dermatitis drug shows improved symptoms
Glenmark Pharmaceuticals has reported positive results from the Phase IIa clinical trial of its investigational candidate GBR 830 in patients with atopic dermatitis. (Source: Drug Development Technology)
Source: Drug Development Technology - July 31, 2017 Category: Pharmaceuticals Source Type: news

Boehringer Ingelheim initiates interchangeability trial of BI 695501 and Humira
Boehringer Ingelheim has initiated patient enrolment in an interchangeability clinical trial (VOLTAIRE-X) of its product candidate BI 695501 and the US-marketed formulation of 40mg/0.8mL Humira. (Source: Drug Development Technology)
Source: Drug Development Technology - July 30, 2017 Category: Pharmaceuticals Source Type: news

AstraZeneca ’s Tagrisso improves progression-free survival in Phase III NSCLC trial
AstraZeneca has reported positive results from the Phase III FLAURA trial of Tagrisso (osimertinib) to treat patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC). (Source: Drug Development Technology)
Source: Drug Development Technology - July 30, 2017 Category: Pharmaceuticals Source Type: news

Cytokinetics evaluates CK-2127107 in Phase II trial to treat ALS
US-based Cytokinetics has started a Phase II FORTITUDE-ALS clinical trial of CK-2127107 for the treatment of patients with amyotrophic lateral sclerosis (ALS). (Source: Drug Development Technology)
Source: Drug Development Technology - July 30, 2017 Category: Pharmaceuticals Source Type: news

Gamlen Appoints ABL & E as Distributor
Gamlen Instruments has appointed ABL&E as the exclusive distributor for Gamlen Instruments in Eastern Europe. (Source: Drug Development Technology)
Source: Drug Development Technology - July 28, 2017 Category: Pharmaceuticals Source Type: news

Genentech ’s Actemra meets primary and secondary endpoints in Phase III trial for GCA
Genentech has reported positive results from the Phase III GiACTA clinical trial of Actemra (tocilizumab) to treat adults with giant cell arteritis (GCA). (Source: Drug Development Technology)
Source: Drug Development Technology - July 27, 2017 Category: Pharmaceuticals Source Type: news

OncoQuest starts enrolment in Phase I/II ovarian cancer trial
Canada-based OncoQuest has started enrolling patients in a Phase I/II clinical trial to evaluate the combination of its antibody oregovomab with Hiltonol as a treatment for ovarian cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - July 27, 2017 Category: Pharmaceuticals Source Type: news

Vosevi ™ for the Retreatment of Chronic Hepatitis C Virus Infection
Vosevi ™ (Sofosbuvir/Velpatasvir/Voxilaprevir) is a direct-acting antiviral (DAA) indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults with genotypes one to six. (Source: Drug Development Technology)
Source: Drug Development Technology - July 27, 2017 Category: Pharmaceuticals Source Type: news